TomoTherapy and Hitachi Medical Corporation Enter Into Distribution Agreement for Japan

MADISON, Wis – Jan. 20, 2009 – TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it has entered into an exclusive agreement with Hitachi Medical Corporation (HMC) to distribute the Hi·Art® cancer treatment system in Japan. Through the agreement, HMC will market, sell and service the innovative Hi·Art system, which facilitates highly precise, CT-guided radiation therapy for a wide range of clinical indications.

“Hitachi Medical Corporation is an ideal partner for us and for our valued customers, in one of our most important markets,” said TomoTherapy CEO Fred Robertson, M.D. “HMC’s robust national infrastructure and reputation for excellent technical and customer support will enhance our ability to service all hospitals in Japan that are currently using TomoTherapy technology. Additionally, this agreement represents a significant opportunity for us to reach new customers, and help advance the quality of cancer care across Japan, the second largest radiation therapy marketplace in the world.”

source: TomoTherapy